PT - JOURNAL ARTICLE AU - Nisreen A Alwan AU - Donna Clutterbuck AU - Marija Pantelic AU - Jasmine Hayer AU - Lere Fisher AU - Lyth Hishmeh AU - Melissa Heightman AU - Gail Allsopp AU - Dan Wootton AU - Asad Khan AU - Claire Hastie AU - Monique Jackson AU - Clare Rayner AU - Darren Brown AU - Emily Parrett AU - Geraint Jones AU - Kerry Smith AU - Rowan Clarke AU - Sammie Mcfarland AU - Mark Gabbay AU - Amitava Banerjee AU - the STIMULATE-ICP Consortium TI - Long Covid active case finding: a co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) AID - 10.1101/2022.08.24.22278954 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.24.22278954 4099 - http://medrxiv.org/content/early/2022/08/25/2022.08.24.22278954.short 4100 - http://medrxiv.org/content/early/2022/08/25/2022.08.24.22278954.full AB - Background and aim Long Covid is a significant public health concern with potentially negative implications for health inequalities. We know that those who are already socially disadvantaged in society are more exposed to COVID-19, experience the worst health outcomes and are more likely to suffer economically. We also know that these groups are more likely to experience stigma and discrimination and have negative healthcare experiences even before the pandemic. However, little is known about disadvantaged groups’ experiences of Long Covid and preliminary evidence suggests they may be under-represented in those who access formal care.We will conduct a pilot study in a defined geographical area (Camden, London, UK) to test the feasibility of a community-based approach of identifying Long Covid cases that have not been formally clinically diagnosed and have not been referred to Long Covid Specialist services. We will explore the barriers to accessing recognition, care and support, as well as experiences of stigma and perceived discrimination.Methods This protocol and study materials were co-produced with a Community Advisory Board (CAB) made up primarily of people living with Long Covid. Working with voluntary organisations, promotional material are co-developed and will be distributed in the local community with engagement from key community organisations and leaders to highlight Long Covid symptoms and invite those experiencing them to participate in the study if they are not formally diagnosed and accessing care. Awareness of Long Covid and symptoms, experiences of trying to access care, as well as stigma and discrimination will be explored through qualitative interviews with participants. Upon completion of the interviews, participants will be offered referral to the local social prescribing team to receive support that is personalised to them potentially including, but not restricted to, liaising with their primary care provider and the regional Long Covid clinic run by University College London Hospitals (UCLH).Ethics and dissemination Ethical approval has been obtained from the Faculty of Medicine Ethics Committee and Research Integrity and Governance, University of Southampton. (reference number 72400). Findings will be reported in a report and submitted for peer-reviewed publication. Definitive methods of dissemination will be decided by the CAB. Summaries of the findings will also be shared on the STIMULATE-ICP website, locally in the study area and through social media. We will specifically target policy makers and those responsible for shaping and commissioning Long Covid healthcare services and social support such as NHSE England Long Covid Group.Competing Interest StatementNAA is a co-investigator on the NIHR-funded HI-COVE study and has contributed in an advisory capacity to WHO and the EU Commission's Expert Panel on effective ways of investing in health meetings in relation to post-COVID-19 condition. GA is Interim CMO for NICE. GJ featured in two 'All Party Parliamentary Group' sessions on Coronavirus. MJ is on the advisory group for the HI-COVE study. CR is Lead for Patient Participation and Involvement on NIHR-funded LoCoMotion study and is a Community Representative for the WHO-affiliated Access to Covid Therapies Accelerator.Funding StatementThis work is supported by NIHR grant number [NIHR COV-LT2-0043]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. DW is supported by an NIHR Advanced Fellowship. MG is part-funded by the Applied Research Collaboration North West Coast (ARC NWC). The views and opinions expressed in this protocol are those of the authors and do not necessarily reflect those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval has been obtained from the Faculty of Medicine Ethics Committee and Research Integrity and Governance, University of Southampton (reference number 72400).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a study protocol with no associated data at this stage.